Last 13 quarters of trend data · Healthcare · Neuroscience Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q1 '27 | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -2.48 | — | — | — | 2.37 | — | — | 0.22 | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 10.49 | — | 5.03 | — | — | — | — | 22.47 | 302.79 | 30.67 | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 0.00 | 0.82 | 0.96 | 0.75 | 0.59 | 2.12 | 0.40 | 51.85 | 58.38 | 72.25 | 48.39 | 58.44 | 83.94 | 236.62 |
| — | -61.2% | +140.9% | -98.6% | -99.0% | -97.1% | -99.2% | -11.3% | -30.4% | -69.5% | — | — | — | — | |
| P/FCF | — | — | 4.87 | — | — | — | 0.04 | 29.42 | — | — | — | — | — | — |
| — | — | +12337.8% | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | 540.87 | — | — | — | — | 27.42 | 73.92 | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | 27.79 | 78.77 | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q1 '27 | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 43.5% | — | 85.9% | — | — | — | 100.0% | 100.0% | 100.0% | -1.6% | — | — | — | — |
| — | — | -14.1% | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | -835.5% | — | -14.0% | — | — | — | 99.1% | 79.8% | 382.4% | -35.5% | — | — | — | — |
| — | — | -114.1% | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | -1145.7% | — | -417.7% | — | — | — | 141.8% | 75.1% | -293.2% | -8.0% | — | — | — | — |
| — | — | -394.5% | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q1 '27 | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -0.1% | -5.9% | -18.2% | -1.7% | 8.8% | -72.4% | -54.1% | 56.7% | -12.6% | -4.7% | -11.2% | 39.3% | -29.0% | -50.1% |
| — | +91.8% | +66.5% | -103.0% | +170.0% | -1455.3% | -382.0% | +44.3% | +56.4% | +90.7% | — | — | — | — | |
| ROA | -0.1% | -5.1% | -15.4% | -1.4% | 5.8% | -42.3% | -40.1% | 46.1% | -9.5% | -3.2% | -9.7% | — | -21.6% | -37.3% |
| — | +87.9% | +61.5% | -103.1% | +161.6% | -1230.4% | -312.2% | — | +56.2% | +91.5% | — | — | — | — | |
| ROIC | -0.1% | -33.1% | -1.7% | -10.0% | -93.1% | -197.8% | -93.6% | 95.9% | 20.2% | -37.2% | -61.6% | -27.9% | -40.1% | -69.3% |
| — | +83.3% | +98.2% | -110.4% | -561.5% | -432.1% | -52.0% | +444.0% | +150.4% | +46.4% | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q1 '27 | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | — | 0.05 | 0.01 |
| — | — | -82.2% | -82.5% | -92.2% | -36.5% | -49.7% | — | -73.2% | 0.0% | — | — | — | — | |
| Debt / EBITDA | — | — | 19.47 | — | — | — | — | 0.01 | 0.07 | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 27.85 | 18.05 | 27.85 | 14.31 | 9.04 | 2.72 | 3.56 | 11.01 | 2.06 | 3.30 | 3.45 | — | 3.81 | 3.30 |
| — | +563.0% | +681.5% | +30.0% | +338.7% | -17.6% | +3.4% | — | -45.9% | -0.0% | — | — | — | — | |
| Quick Ratio | 27.85 | 18.05 | 27.85 | 14.31 | 9.04 | 2.72 | 3.56 | 11.01 | 2.06 | 3.30 | 3.45 | — | 3.81 | 3.30 |
| — | +563.0% | +681.5% | +30.0% | +338.7% | -17.6% | +3.4% | — | -45.9% | -0.0% | — | — | — | — | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 13 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying NEUP stock.
Neuphoria Therapeutics Inc.'s current P/E is -2.5x. The average P/E over the last 1 quarters is 2.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Neuphoria Therapeutics Inc.'s current operating margin is -835.5%. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Neuphoria Therapeutics Inc.'s business trajectory between earnings reports.